Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$15.08 USD
+0.20 (1.34%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $15.07 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.08 USD
+0.20 (1.34%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $15.07 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth A Momentum A VGM
Zacks News
How Do Earnings Impact The Stock Market?
by Panel Of Zacks Experts
Q2 Earnings Season is in full swing and Sheraz Mian joins the show to discuss everything you need to know!
Seattle Genetics (SGEN) Q2 Loss Narrows, Sales Top Estimates
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates and rides high on revenue beat in Q2.
J&J Submits BLA for Subcutaneous Formulation of Darzalex
by Zacks Equity Research
Johnson & Johnson (JNJ) submits a BLA to the FDA, seeking approval for a subcutaneous formulation of its multiple myeloma drug.
Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.
J&J's Darzalex Gets FDA Nod for First-Line Multiple Myeloma
by Zacks Equity Research
Johnson & Johnson's (JNJ) label expansion application, seeking approval for Darzalex+Revlimid to treat transplant ineligible newly diagnosed patients with multiple myeloma, receives FDA approval.
AbbVie Announces Lifting of FDA's Partial Hold on CANOVA Study
by Zacks Equity Research
AbbVie (ABBV) receives encouraging news as FDA lifts partial clinical hold on a late-stage study evaluating Venclexta in relapsed/refractory multiple myeloma.
Verastem Up on Positive Data From Early-Stage Copiktra Study
by Zacks Equity Research
Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.
Kamada (KMDA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Kamada (KMDA) is expected to provide updates on pipeline candidates during the first-quarter earnings call.
Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y
by Zacks Equity Research
Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.
What's in the Cards for Sunesis (SNSS) This Earnings Season?
by Zacks Equity Research
Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.
Zoetis (ZTS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Seattle Genetics (SGEN) Q1 Loss Narrows, Revenues Top Mark
by Zacks Equity Research
Seattle Genetics (SGEN) betters loss estimates in Q1 and also rides high on revenue beat.
Top Ranked Income Stocks to Buy for April 25th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 25th
Kamada to Begin Phase III Study for Inhaled AAT Product in 2H
by Zacks Equity Research
Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.
Takeda Pharmaceutical Enters Oversold Territory
by Zacks Equity Research
Takeda Pharmaceutical Company Limited (TAK) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Will Ironwood Suffer From Dependence on Linzess' Progress?
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) Linzess sales are rising and pipeline candidates are progressing well. The company completes separation of its sGC business.
Moving Average Crossover Alert: Takeda Pharmaceutical
by Zacks Equity Research
Takeda Pharmaceutical Company Limited (TAK) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Company News For Mar 5, 2019
by Zacks Equity Research
Companies in the news are; PLCE, BIIB, NITE, ASND and TAK
5 Tiny Biotech Stocks With Superb Growth Potential
by Swarup Gupta
A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.
Ironwood to Get New CEO, Current CEO to Head Latest Spinoff
by Zacks Equity Research
Ironwood Pharma (IRWD) appoints AstraZeneca executive, Mark Mellon, as its new chief executive officer. Peter Hecht, the current CEO, will lead the new spinoff company focusing on rare disease.